Spots Global Cancer Trial Database for BN80927 in Patients With Advanced Malignant Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: BN80927 in Patients With Advanced Malignant Solid Tumors
Official Title: A Phase I Dose Finding Study of BN80927 Administered as an Intravenous Infusion Once Every 3 Weeks in Patients With Advanced Malignant Solid Tumors
Study ID: NCT01435096
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study was to determine the maximum tolerated dose and the recommended dose of BN80927 in patients with advanced malignant solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Centre Paul Papin, Angers, , France
Centre Eugene Marquis, Rennes, , France
Centre Rene Huguenin, Saint-Cloud, , France
Contact Details
Name: Ipsen Study Director
Affiliation: Ipsen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
